Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19539399 | 0.77 | POLB (0.38) | POLBMEN1KMT2APKMMAPT | |
| SCHEMBL1179957 | 0.75 | KDM4E (0.36) | MEN1KMT2APKMMAPTTDP1 | |
| SCHEMBL2846447 | 0.75 | TSHR (0.55) | POLBMEN1KMT2APKMMAPT | |
| SCHEMBL7012885 | 0.71 | NPSR1 (0.41) | POLBMEN1KMT2AMAPTTDP1 | |
| SCHEMBL19539400 | 0.71 | PRMT1 (0.40) | POLBMEN1KMT2AMAPTTDP1 | |
| SCHEMBL2533704 | 0.66 | TPMT (0.40) | POLBMEN1KMT2AMAPTTDP1 | |
| SCHEMBL21076665 | 0.66 | MAPT (0.38) | MEN1KMT2APKMMAPTTDP1 | |
| SCHEMBL1317366 | 0.65 | MAOA (0.48) | POLBMEN1KMT2APKMMAPT | |
| SCHEMBL3668058 | 0.64 | ALDH1A1 (0.45) | POLBMEN1KMT2APKMMAPT | |
| SCHEMBL17585433 | 0.64 | MAPT (0.46) | POLBMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3450433-B1 | PURINE DERIVATIVES AS TLR7 INHIBITORS FOR TREATING E.G. SYSTEMIC LUPUS ERYTHEMATOSUS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2021-08-18 | — | — | EP | disclosed |
| US-10703755-B2 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703755-B2 | Substituted purine derivative | TLR7, TLR9, TLR1 | POLB 1496/4885MEN1 3087/4885KMT2A 982/4885 |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | TLR7, TLR9, TLR1 | POLB 1496/4885MEN1 3087/4885KMT2A 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.